Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Study Overview
=================
Brief Summary
-----------------
This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 480 subjects are to be randomized into 1 of 4 possible treatment groups (investigational Influenza Vaccine or licensed Quadrivalent Influenza Vaccine comparators) at 120 participants per group. Every participant will receive an influenza vaccine injection on Day 1 and will be followed up for approximately 6 months following injection. The primary immunogenicity analysis is based on Day 29 serum.

Official Title
-----------------
A Phase 2, Randomized, Stratified, Observer-Blind Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Older Adults

Conditions
-----------------
Influenza, Human

Intervention / Treatment
-----------------
* Biological: Investigational aIIV4c
* Biological: IIV4c type 1
* Biological: aIIV4
* Biological: RIV4 type 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals 50 years of age and older on the day of informed consent. Individuals who have voluntarily given written consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. Individuals who can comply with study procedures including follow-up. Males, females of non-childbearing potential or females of childbearing potential who are using an effective birth control method, at least 30 days prior to informed consent, which they intend to use for at least 2 months after the study vaccination. Exclusion Criteria: Females of childbearing potential who are pregnant, lactating, or who have not adhered to a specified set of contraceptive methods from at least 30 days prior to informed consent and who do not plan to do so until 2 months after the study vaccination. Progressive, unstable or uncontrolled clinical conditions. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study. History of any medical condition considered an adverse event of special interest. Known history of Guillain Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis. Clinical conditions representing a contraindication to intramuscular administration of vaccines or blood draw. Abnormal function of the immune system resulting from: Clinical conditions Systemic administration of corticosteroids (PO/IV/IM) at a dose of ≥ 20 mg/day of prednisone or equivalent for more than 14 consecutive days within 90 days prior to informed consent5. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent. Received immunoglobulins or any blood products within 180 days prior to informed consent. Received an investigational or non-registered medicinal product within 30 days prior to vaccination. Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 28 days from the study vaccines. Study personnel or immediate family or household member of study personnel. Receipt of any influenza vaccine within 6 months prior to vaccination in this study, or plan to receive an influenza vaccine during the study period. Acute (severe) febrile illness Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Investigational aIIV4c group<br>aIIV4c will be administered as a single dose intramuscularly on Day 1 | Biological: Investigational aIIV4c<br>* Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.<br>|
| Active Comparator: licensed IIV4c type 1 group<br>IIV4c will be administered as a single dose intramuscularly on Day 1 | Biological: IIV4c type 1<br>* Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.<br>|
| Active Comparator: licensed aIIV4 group<br>aIIV4 will be administered as a single dose intramuscularly on Day 1 | Biological: aIIV4<br>* Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.<br>|
| Active Comparator: licensed RIV4 type 2 group<br>RIV4 will be administered as a single dose intramuscularly on Day 1 | Biological: RIV4 type 2<br>* Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunogenicity Endpoint: Hemagglutination inhibition (HI) titers against vaccine A and B influenza strains |  | 28 days post-vaccination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Endpoint: The Percentage of Subjects With Solicited Local and Systemic Reactions |  | 7 days post-vaccination | 
| Safety Endpoint: The Percentage of Subjects with Unsolicited Adverse Events |  | 28 days post-vaccination | 
| Safety Endpoint: The Percentage of Subjects with Serious Adverse Events (SAEs), AEs Leading to Withdrawal, Adverse Events of Special Interest (AESI) and Medically Attended Adverse Events (MAAEs) |  | 180 days post-vaccination | 
| Immunogenicity Endpoint: Microneutralization (MN) titers against vaccine A and B influenza strains |  | 28 days post-vaccination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Influenza, Vaccine, MF59, Adjuvant